Biotech

All Articles

Actinogen's cortisol blocker falls short stage 2 depression research

.Actinogen Medical's cortisol blocker has actually missed out on the main endpoint of a period 2 res...

Bivictrix makes a decision going personal only means to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have actually gone to the facility of a lot of a billion-dollar bio...

TPG leadings up funds to $580M for investments throughout lifestyle sciences

.Resource manager TPG, which has actually sustained biotechs such as Sionna Therapeutics and also Sa...

Merck ceases stage 3 TIGIT test in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT plan has endured an additional problem. Months after shuttering a phase 3 ca...

After a challenging year, Exscientia folds up right into Recursion

.After a year determined through pipeline hairstyles, the departure of its own CEO and also cutbacks...

Cullinan, after $25M bargain, hands back bispecific to Port

.Cullinan Rehab was actually made an impression on sufficient along with Port BioMed's bispecific in...

A closer take a look at Ferocious Biotech's Tough 15

.In this particular full week's incident of "The Leading Line," our company are actually diving righ...

Lilly deals with stage 2 failure of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's gathering celebrating the commendati...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our summary of considerable leadership hirings, firings a...

Lykos will talk to FDA to reevaluate its selection adhering to denial of MDMA therapy for trauma

.Complying with an inadequate showing for Lykos Therapeutics' MDMA applicant for trauma at a recent ...